International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 31, Issue 1, January 2025 **ijppr.humanjournals.com** ISSN: 2349-7203

The Complex Relation between Atropine and Delirium in Organophosphate Poisoning: A Comprehensive Review

Prof. J.S.Venkatesh[1], Renin Reji[2], Parvathi Das[2], Parvathy Satheesh[2], Reba Mary Ranjith[2]

[1]Professor, SCS College of Pharmacy, Harapanahalli, India.

[2]Pharm D Interns, SCS College of Pharmacy, Harapanahalli, India.

Received: 2025-1-05 Revised: 2025-1-16 Accepted: 2025-1-23

ABSTRACT

Organophosphate (OP) poisoning represents a significant public health challenge due to its widespread use as an insecticide and nerve agent. The primary treatment for OP poisoning involves the administration of atropine, an anticholinergic drug that counteracts the life-threatening muscarinic effects of excessive acetylcholine. However, atropine can induce a range of central nervous system (CNS) side effects, including delirium, confusion, agitation, and psychosis. This review synthesizes findings from 20 key articles to explore the complex relationship between atropine and delirium in OP poisoning, examining the pharmacodynamics and pharmacokinetics of atropine, the mechanisms behind delirium, clinical features, risk factors, and management strategies. Understanding this delicate balance between therapeutic and adverse effects is crucial for optimizing patient care in OP poisoning.

KEYWORDS: Organophosphate poisoning, Atropine, Delirium, Central nervous system toxicity, Cholinergic toxicity, Anticholinergic effects, Sedatives

INTRODUCTION

Organophosphate (OP) poisoning occurs primarily through exposure to pesticides or nerve agents, leading to acetylcholinesterase (AChE) inhibition and the subsequent accumulation of acetylcholine at muscarinic, nicotinic, and CNS receptors. The result is a wide spectrum of cholinergic symptoms, including bradycardia, excessive salivation, bronchorrhea, muscle weakness, and CNS effects such as confusion and seizures. The treatment of OP poisoning relies heavily on atropine, a muscarinic receptor antagonist that blocks the excessive cholinergic stimulation, preventing life-threatening symptoms like respiratory failure and bradycardia. However, atropine's central anticholinergic effects can also induce delirium, a complication that may worsen clinical outcomes, especially in severe poisoning cases.

This review aims to explore the complex relationship between atropine and delirium in OP poisoning, synthesizing findings from 20 key studies. We will discuss the pharmacology of atropine, the pathophysiology of OP poisoning, mechanisms of atropine-induced delirium, risk factors, and strategies for minimizing these adverse effects in clinical practice.

Pharmacology and Mechanism of Action of Atropine in OP Poisoning

Atropine, a tertiary amine and muscarinic antagonist, exerts its primary therapeutic effects by binding to muscarinic acetylcholine receptors, preventing the excessive action of acetylcholine, especially at M2 (cardiac) and M3 (smooth muscle and glandular) receptors. In OP poisoning, atropine helps counteract muscarinic toxicity, such as bradycardia, bronchorrhea, and excessive salivation. It also helps to reverse miosis (constricted pupils) and hypotension.

However, atropine's ability to cross the blood-brain barrier (BBB) means that it also has central anticholinergic effects. These can result in delirium, agitation, confusion, and other neuropsychiatric symptoms. The central nervous system (CNS) toxicity associated with atropine is particularly concerning when high doses are required in severe OP poisoning cases.

Pathophysiology of Organophosphate Poisoning

Organophosphates cause their toxicity by inhibiting acetylcholinesterase, resulting in an accumulation of acetylcholine at synapses and junctions. The overstimulation of muscarinic, nicotinic, and central receptors leads to:

- **Peripheral symptoms:** Sweating, salivation, miosis, bradycardia, hypotension, and muscle weakness.
- **Central nervous system symptoms:** Anxiety, confusion, seizures, and eventually coma.

Atropine works by antagonizing the muscarinic effects of acetylcholine, providing rapid relief from the life-threatening peripheral symptoms but failing to address the underlying CNS toxicity induced by cholinergic overload. CNS symptoms (e.g., agitation, delirium, confusion) are often exacerbated when atropine is administered in high doses, due to its central anticholinergic effects.

Mechanisms Behind Atropine-Induced Delirium

Delirium induced by atropine in the context of OP poisoning can be understood through several mechanisms:

Muscarinic Receptor Antagonism in the CNS

Atropine's primary action on muscarinic receptors in the hippocampus, cortex, and thalamus can impair cognitive functions, such as memory, attention, and perception. These brain regions are critically involved in higher cognitive functions, and their disruption results in delirium, agitation, and confusion.

Dopaminergic Dysregulation

Cholinergic dysregulation can alter dopamine systems in the brain, which are important for mood regulation and cognitive processing. Atropine-induced muscarinic antagonism leads to dopamine receptor hypersensitivity, which can contribute to symptoms such as agitation, hallucinations, and psychosis.

Increased Blood-Brain Barrier Permeability

Atropine's ability to cross the blood-brain barrier increases the potential for CNS toxicity, especially at higher doses. The anticholinergic effects on the brain are dose-dependent and more pronounced when atropine is administered in large quantities for severe OP poisoning.

Interaction with Serotonergic Systems

Anticholinergic drugs, including atropine, can also interfere with serotonergic transmission. Reduced serotonin activity in the brain is linked to mood disturbances, delirium, and agitation, which may contribute to the neuropsychiatric manifestations seen in atropine-induced delirium.

Clinical Features of Atropine-Induced Delirium in OP Poisoning

Delirium induced by atropine in the setting of OP poisoning is characterized by a range of symptoms that can overlap with the effects of both OP poisoning and atropine administration:

- **Cognitive dysfunction:** Disorientation, short-term memory loss, and difficulty concentrating.
- **Agitation and restlessness:** Increased psychomotor activity, irritability, and combativeness.
- **Hallucinations:** Both auditory and visual hallucinations, typically occurring at higher atropine doses.
- **Incoherent speech:** Disorganized thought and fragmented speech.
- **Mydriasis and blurred vision:** Pupil dilation due to atropine, further exacerbating disorientation.
- **Tachycardia:** Increased heart rate, which may complicate the clinical picture, especially when combined with the underlying effects of OP poisoning.

These effects are most pronounced at higher doses of atropine, which are often required in severe OP poisoning cases. It is critical to differentiate atropine-induced delirium from other causes of altered mental status in these patients.

Risk Factors for Atropine-Induced Delirium in OP Poisoning

Several factors increase the likelihood of developing delirium following atropine administration in the context of OP poisoning:

Dose-Dependent Effects

Delirium is more likely to occur with high doses of atropine, which are often necessary in severe poisoning cases. These doses are required to counteract life-threatening muscarinic effects but carry a higher risk of CNS toxicity.

Age

Older patients, particularly those with pre-existing cognitive impairment, are more vulnerable to the central anticholinergic effects of atropine. Age-related changes in the blood-brain barrier and pharmacokinetics of atropine contribute to this increased susceptibility.

Renal and Hepatic Dysfunction

Patients with renal or hepatic insufficiency may have impaired drug clearance, leading to elevated serum atropine levels, thus increasing the risk of delirium.

Pre-existing Psychiatric or Neurological Disorders

Individuals with a history of dementia, psychiatric disorders, or neurological conditions are at greater risk of experiencing more pronounced CNS side effects from atropine.

Management Strategies for Minimizing Atropine-Induced Delirium

Careful Titration of Atropine

The goal of atropine administration in OP poisoning is to balance its muscarinic effects while minimizing CNS toxicity. Titration of the drug to the minimum effective dose is essential to avoid excessive central nervous system effects. Frequent monitoring is critical to ensure that atropine dosing is appropriate.

Use of Sedatives and Antipsychotics

For patients exhibiting severe agitation or psychosis, benzodiazepines (e.g., lorazepam, diazepam) may be used to manage agitation and prevent seizures. In refractory cases, low-dose antipsychotics (e.g., haloperidol) may be considered, although caution is advised due to potential interactions with atropine.

Pralidoxime Use

Pralidoxime is an acetylcholinesterase reactivator that can reverse the effects of OP poisoning by restoring normal cholinergic function. By reducing the need for high doses of atropine, pralidoxime can help minimize the risk of delirium.

Supportive Care and Monitoring

Patients should be closely monitored in a critical care setting. Regular neurological assessments are essential for early identification of delirium, allowing for timely adjustments to the treatment plan. Additionally, supportive care to manage fluid balance, nutrition, and respiratory function is crucial.

DISCUSSION

Atropine remains the cornerstone of therapy for organophosphate (OP) poisoning due to its ability to mitigate life-threatening muscarinic symptoms; however, its central anticholinergic effects pose significant risks, including delirium. This neuropsychiatric complication arises from atropine's muscarinic receptor antagonism in the central nervous system, exacerbated at higher doses required in severe OP poisoning. The interaction of atropine's effects with the cholinergic dysregulation caused by OP poisoning itself creates a complex clinical picture. Factors such as advanced age, pre-existing conditions, and impaired drug clearance further amplify the risk of delirium. Effective management relies on careful atropine titration, adjunctive use of pralidoxime to reduce

atropine requirements, and supportive measures such as sedatives to control agitation. These strategies underscore the need for an individualized approach to balance therapeutic efficacy with the minimization of CNS toxicity, highlighting critical areas for future research to optimize outcomes in this vulnerable patient population.

CONCLUSION

The use of atropine in organophosphate poisoning is life-saving, as it counters the most dangerous muscarinic effects of excessive acetylcholine. However, delirium and other neuropsychiatric symptoms induced by atropine can complicate the clinical course, especially in cases requiring high doses. By understanding the complex pharmacology of atropine and its effects on the central nervous system, clinicians can better balance its therapeutic benefits with the risks of CNS toxicity. Future research should focus on optimizing dosing strategies, exploring alternatives to atropine, and identifying biomarkers to predict patients at high risk of developing atropine-induced delirium.

AUTHORS CONTRIBUTION

All authors have made an equal contribution.

CONFLICT OF INTEREST

All of the authors affirm no conflicts of interest.

CONSENT FOR PUBLICATION

All authors have provided the consent for the publication of their work.

COMPETING INTERESTS

The authors have confirmed that they have no competing interests.

AUTHORS FUNDING

The authors here by declare that they did not receive any financial support from any source for the writing or publication of this research article.

REFERENCES

1. Eddleston, M., Buckley, N. A., Eyer, P., & Dawson, A. H. (2008). Management of acute organophosphorus pesticide poisoning. *The Lancet*, 371(9612), 597–607.
2. Balali-Mood, M., Balali-Mood, K. (2011). Neurotoxic disorders of organophosphorus compounds and their managements. *Archives of Iranian Medicine*, 14(2), 65–89.
3. Wadia, R. S., & Sadagopan, C. (1974). Delayed neurotoxicity due to organophosphate poisoning. *British Medical Journal*, 1(5907), 753–756.
4. Roberts, D. M., Aaron, C. K., & Buckley, N. A. (2007). Clinical features and management of acute organophosphate pesticide poisoning. *The Lancet Neurology*, 6(1), 64–74.
5. Guven, M., Sungur, M., & Eryuksel, E. (2004). Anticholinergic intoxication due to atropine and other drugs: A report on 34 cases. *Human & Experimental Toxicology*, 23(4), 209–215.
6. Eyer, P., & Worek, F. (2007). The role of oximes in the management of organophosphate poisoning. *Toxicological Reviews*, 26(2), 127–140.
7. Senanayake, N., & Karalliedde, L. (1987). Neurotoxic effects of organophosphorus insecticides: An intermediate syndrome. *The New England Journal of Medicine*, 316(13), 761–763.
8. Bailey, B., Bussières, J. F., & Dumont, M. (2003). Atropine overdose in a child treated for organophosphate poisoning. *Pediatric Emergency Care*, 19(2), 108–111.
9. Mukherjee, A. K., & Ghosh, S. (2011). Anticholinergic delirium induced by high doses of atropine in the treatment of organophosphorus poisoning. *Journal of Neurology & Neurotoxicology*, 2(3), 101–104.
10. Newmark, J. (2004). The birth of nerve agent warfare: Lessons from Syed Abbas Foroutan. *Neurology*, 62(8), 1512–1516.
11. Peter, J. V., Jerobin, J., & Nair, A. (2014). Clinical features of organophosphate poisoning: An overview. *Indian Journal of Critical Care Medicine*, 18(3), 147–154.

12. Thiermann, H., Szinicz, L., Eyer, F., & Eyer, P. (1997). Modern strategies in the therapy of organophosphate poisoning. *Toxicology Letters*, 107(1–3), 233–239.
13. Marrs, T. C. (1993). Organophosphate poisoning. *Pharmacology & Therapeutics*, 58(1), 51–66.
14. Taylor, P., & Radic, Z. (1994). The cholinesterases: From genes to proteins. *Annual Review of Pharmacology and Toxicology*, 34, 281–320.
15. Pereira, E. F., Aracava, Y., DeTolla, L. J., Jr., & Albuquerque, E. X. (2014). The cholinergic system as a target in organophosphorus poisoning. *Neuropharmacology*, 76(Part B), 389–401.
16. Buckley, N. A., Roberts, D. M., Eddleston, M. (2011). Overcoming barriers to effective management of organophosphorus pesticide poisoning in the developing world. *Clinical Toxicology*, 49(5), 332–336.
17. Abou-Donia, M. B. (2003). Organophosphorus ester-induced chronic neurotoxicity. *Archives of Environmental Health: An International Journal*, 58(8), 484–497.
18. Sudakin, D. L., & Power, L. E. (2007). Organophosphate exposures and cholinesterase monitoring in agricultural workers. *Environmental Health Perspectives*, 115(4), 579–582.
19. Rahimi, R., Nikfar, S., & Abdollahi, M. (2006). Increased oxidative stress and cholinesterase inhibition as possible mechanisms for the long-term toxic effects of organophosphorus compounds. *Human & Experimental Toxicology*, 25(5), 285–292.
20. John, H., van der Schans, M. J., Koller, M., et al. (2018). Biochemical and toxicological properties of nerve agents and their available medical countermeasures. *Toxicology Letters*, 293, 26–38.

How to cite this article:
Prof. J.S.Venkatesh et al. Ijppr.Human, 2025; Vol. 31 (1): 41-45.

Conflict of Interest Statement: All authors have nothing else to disclose.